Refractory & Super-Refractory Status Epilepticus

ABPN Neurocritical Care Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Neurologic Examination & Coma Assessment in the ICU

Current Examination, Blueprint & Preparation Neurologic Examination in Critically Ill Patients Coma Evaluation & Consciousness Alterations Delirium & Toxic-Metabolic Encephalopathy in the ICU

2 Chapter 2: Cerebral Physiology & Intracranial Dynamics

Cerebral Blood Flow, Metabolism & Autoregulation Intracranial Pressure & Compliance Cerebral Edema & Herniation Syndromes

3 Chapter 3: Intracranial Hypertension & Cerebral Perfusion Management

Tiered ICP Management Protocols Hyperosmolar Therapy & Fluid Management Advanced & Refractory ICP Interventions

4 Chapter 4: Airway, Mechanical Ventilation & Pulmonary ICU Management

Emergency Airway Management & Neuro-Intubation Mechanical Ventilation Strategies in Acute Brain Injury Tracheostomy & Ventilator Weaning in Neurocritical Care Pulmonary Complications in the Neuro-ICU Obstructive Lung Disease, Pulmonary Hypertension & Bronchoscopy

5 Chapter 5: Hemodynamics, Shock & Cardiovascular Management

Hemodynamic Monitoring & Blood Pressure Targets Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives Cardiac Complications of Brain Injury

6 Chapter 6: Neuropharmacology, Analgesia & Sedation

ICU Sedation & Analgesia Neuromuscular Blockade & Monitoring Propofol Infusion Syndrome & Drug Toxicities Antiseizure Drug Pharmacology in the ICU

7 Bleeding, Thrombosis & Hematologic Emergencies

Warfarin & Heparin Reversal Direct Oral Anticoagulant (DOAC) Reversal Antiplatelet Management & Platelet Dysfunction Venous Thromboembolism Prophylaxis & Management Transfusion, Coagulopathy, TMA & Cellular-Therapy Neurotoxicity

8 Chapter 8: Systemic ICU Care, Fluids, Electrolytes & Endocrine

Hyponatremia & Osmoregulation: SIADH vs Cerebral Salt Wasting Diabetes Insipidus, Hypernatremia & Endocrine Crises Critical Care Prophylaxis, Nutrition & Infection Prevention

9 Systemic Trauma & Environmental Injury

Polytrauma, Chest Injury & Abdominal Hemorrhage Burns, Electrical Injury & Hanging

10 Cardiac Emergencies & Mechanical Support

IABP, Ventricular Devices & ECMO Acute Coronary, Valvular, Rhythm & Aortic Emergencies

11 Kidney Injury, Acid–Base & Renal Replacement

Acute Kidney Injury & Renal Drug Clearance Acid–Base Disorders, Electrolytes & Renal Replacement

12 Systemic Infection & Endocrine Emergencies

Sepsis, Endocarditis & Antimicrobial Principles Thyroid, Adrenal & Dysglycemic Emergencies

13 Gastrointestinal & Hepatic Emergencies

Acute Abdomen, GI Bleeding & Abdominal Compartment Syndrome Acute Liver Failure, Cirrhosis & Hepatic Drug Effects

14 Chapter 9: Neuroimaging in the Neuro-ICU

Non-Contrast CT & CT Angiography CT Perfusion & Advanced Perfusion Imaging Magnetic Resonance Imaging in Critical Illness

15 Chapter 10: Electrophysiology & Neuromonitoring

Continuous EEG & ACNS Standardized Critical Care Terminology Invasive Neuromonitoring: ICP & External Ventricular Drains Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler

16 Angiography, Electrodiagnosis & CSF Analysis

Conventional Angiography & Cranial–Spinal Shunts EMG, Nerve Conduction & Acute Muscle Disease CSF Analysis: Infection, Inflammation & Hemorrhage

17 Chapter 11: Bedside Procedures, Ultrasound & Death by Neurologic Criteria

Critical Care Procedural Skills Critical Care Ultrasound & Echocardiography Determination of Death by Neurologic Criteria

18 Chapter 12: Acute Ischemic Stroke & Reperfusion Therapies

Acute Ischemic Stroke Management & Thrombolysis Endovascular Thrombectomy & Large Vessel Occlusion Malignant Hemispheric & Cerebellar Infarction

19 Chapter 13: Spontaneous Intracerebral Hemorrhage & Intraventricular Hemorrhage

Acute Intraparenchymal Hemorrhage Management Intraventricular Hemorrhage & Hydrocephalus Surgical Evacuation & Minimally Invasive Surgery in ICH

20 Chapter 14: Aneurysmal Subarachnoid Hemorrhage & Delayed Cerebral Ischemia

Aneurysmal Subarachnoid Hemorrhage: Acute Resuscitation & Securing Delayed Cerebral Ischemia & Cerebral Vasospasm Non-Aneurysmal Subarachnoid Hemorrhage & Vascular Malformations

21 Venous, Spinal & Traumatic Vascular Disease

Cerebral Venous Thrombosis & Spinal Cord Infarction Traumatic Dissection, Carotid–Cavernous Fistula & Penetrating Injury

22 Chapter 15: Traumatic Brain & Spinal Cord Injury

Severe Traumatic Brain Injury & Contusions Acute Traumatic Spinal Cord Injury & Neurogenic Shock Spine Trauma, Fractures & Cord Syndromes

23 Chapter 16: Status Epilepticus, Seizures & Neuromuscular Emergencies

Status Epilepticus: Convulsive & Non-Convulsive Refractory & Super-Refractory Status Epilepticus Acute Neuromuscular Respiratory Failure

24 Chapter 17: Post-Cardiac Arrest Care, CNS Infections & Encephalitis

Targeted Temperature Management & Post-Cardiac Arrest Care Post-Cardiac Arrest Neuroprognostication Acute CNS Infections, Encephalitis & Inflammatory Emergencies

25 Neuroinflammation & Neurooncology

Fulminant Demyelination & Autoimmune Encephalitis Brain, Spinal & Leptomeningeal Cancer Emergencies

26 Pregnancy, Transplantation & Pediatric Care

Pregnancy, Postpartum & Post-Transplant Neurologic Care Pediatric Neurocritical Care

27 Chapter 18: Neurosurgical & Perioperative Emergencies

Postoperative Neurosurgical Complications Device Complications: EVDs, Shunts & ICP Monitors Cerebral Hyperperfusion Syndrome & Post-Interventional Emergencies

28 Chapter 19: Ethics, Palliative Care & Organ Donation in the Neuro-ICU

Communication, Surrogate Decision-Making & Conflict Resolution Neuroprognostication Ethics, Withdrawal of Life Support & Palliative Care Organ Donation & Management of the Deceased Donor

Refractory & Super-Refractory Status Epilepticus

Key Takeaways Explain This Topic AI

RSE persists despite adequate initial benzodiazepine and second-line IV therapy; SRSE continues or recurs at least 24 hours after anesthetic initiation.

Anesthetic treatment needs continuous EEG and hemodynamic support, with depth and weaning individualized to response and toxicity.

A fixed burst interval, page count, or suppression percentage is not a universal evidence-based target.

PRIS risk increases with dose and duration, but lower exposure does not guarantee safety; stop propofol promptly if the syndrome is suspected.

NORSE/FIRES requires urgent etiologic investigation; early immunotherapy consideration and escalation are specialist, largely consensus-based decisions.

Last updated: October 2026

Refractory & Super-Refractory Status Epilepticus

When status epilepticus fails to terminate after first- and second-line pharmacotherapy, it enters advanced stages associated with high mortality ( 30 – 50 % 30\text{--}50\% 30 – 50% ) and severe cognitive morbidity. Successful termination of refractory status epilepticus ( R S E RSE RSE ) and super-refractory status epilepticus ( S R S E SRSE SRSE ) requires continuous neuromonitoring, deep anesthetic titrations, and targeted reversal of molecular excitotoxicity.

• Operational Definitions & Synaptic Receptor Trafficking
• Consensus Definitions

Refractory Status Epilepticus (RSE): Status epilepticus that persists clinically or electrographically despite the administration of adequate, weight-adjusted doses of an initial benzodiazepine (Phase 1) and at least one appropriate second-line non-sedating intravenous antiseizure medication (Phase 2). Approximately 25 – 40 % 25\text{--}40\% 25 – 40% of status epilepticus cases become refractory.

Super-Refractory Status Epilepticus (SRSE): Status epilepticus that continues or recurs ≥ 24 hours \ge 24\text{ hours} ≥ 24 hours after the initiation of continuous general anesthetic infusions, including cases where seizures re-emerge during or following the weaning of anesthetic infusions. SRSE carries an in-hospital mortality exceeding 40 % 40\% 40% .

Molecular Receptor Trafficking and Pharmacoresistance

The transition from early status epilepticus to refractory states is governed by rapid, activity-dependent receptor trafficking at the synaptic membrane:

GABA-A Receptor Internalization: During ongoing seizure activity, continuous massive excitation drives calcium influx that activates protein kinases and calcineurin. Within 15 to 30 minutes, post-synaptic G A B A A GABA_A G A B A A ​ receptor subunits (particularly β 2 / β 3 \beta_2/\beta_3 β 2 ​ / β 3 ​ and γ 2 \gamma_2 γ 2 ​ ) become dephosphorylated, interact with the AP2 adaptor complex, and undergo rapid clathrin-mediated endocytosis . As functional G A B A A GABA_A G A B A A ​ receptors are internalized into the endosomal pool, synaptic inhibitory currents decrease up to 20-fold, rendering benzodiazepines and standard GABAergic agents progressively ineffective.

NMDA and AMPA Receptor Translocation: Concurrently, subsynaptic scaffolding proteins (PSD-95) recruit ionotropic glutamate receptors ( N M D A NMDA NM D A receptor GluN1/GluN2B subunits and calcium-permeable A M P A AMPA A MP A receptors) from perisynaptic and intracellular stores, translocating them directly into the post-synaptic active zone. This induces persistent, uncontrolled inward calcium and sodium currents, cementing self-sustaining epileptiform discharges, mitochondrial depolarization, and excitotoxic cell death.

Synaptic Component Early Phase ( 0 – 15 min 0\text{--}15\text{ min} 0 – 15 min ) Refractory Phase ( > 30 – 60 min > 30\text{--}60\text{ min} > 30 – 60 min ) Therapeutic Consequence

Synaptic G A B A A GABA_A G A B A A ​ Receptors Abundant on post-synaptic active membrane Massive clathrin-dependent endocytosis and degradation Benzodiazepines and phenobarbital suffer marked loss of efficacy.

Synaptic N M D A NMDA NM D A / A M P A AMPA A MP A Receptors Normal baseline density Marked upregulation and membrane translocation Excitotoxicity accelerates; provides mechanistic rationale for Ketamine .

Neuropeptide Modulators Pro-convulsant peptides stored Substance P upregulated; inhibitory Neuropeptide Y depleted Loss of endogenous seizure termination cascades.

Blood-Brain Barrier ( B B B BBB BBB ) Intact basal lamina Albumin extravasation and microglial activation Astrocytic potassium buffering impaired via downregulation of Kir4.1.

Continuous Intravenous Anesthetic Infusions

Once RSE is diagnosed, the patient requires emergent endotracheal intubation, mechanical ventilation, invasive arterial blood pressure monitoring, and continuous video-EEG ( c E E G cEEG c EEG ) to guide continuous intravenous anesthetic titrations.

Anesthetic Agent Comparison

Midazolam: Administered as an IV loading bolus of 0.2 mg/kg 0.2\text{ mg/kg} 0.2 mg/kg (repeat boluses of 0.1 – 0.2 mg/kg 0.1\text{--}0.2\text{ mg/kg} 0.1 – 0.2 mg/kg every 5 minutes until seizures cease), followed by a continuous infusion of 0.05 – 2.0 mg/kg/h 0.05\text{--}2.0\text{ mg/kg/h} 0.05 – 2.0 mg/kg/h . Midazolam has a rapid onset and favorable hemodynamic stability compared to barbiturates. However, prolonged infusions trigger acute tachyphylaxis (further G A B A A GABA_A G A B A A ​ receptor downregulation) and accumulation of the active lipophilic metabolite 1 -hydroxymidazolam 1\text{-hydroxymidazolam} 1 -hydroxymidazolam , leading to prolonged sedation in renal failure.

Propofol: Administered as an IV bolus of 1 – 2 mg/kg 1\text{--}2\text{ mg/kg} 1 – 2 mg/kg over 5 minutes, followed by an infusion of 2 – 10 mg/kg/h 2\text{--}10\text{ mg/kg/h} 2 – 10 mg/kg/h (approximately 33–167 micrograms/kg/min). Propofol acts as a potent G A B A A GABA_A G A B A A ​ receptor allosteric agonist and slow-channel blocker with additional actions on other ion channels and neurotransmitter systems. Its ultra-short distribution half-life allows rapid neurological wake-up tests.

Pentobarbital / Thiopental: Barbiturates directly open G A B A A GABA_A G A B A A ​ chloride channels even in the absence of endogenous GABA (barbiturate gating), providing potent suppression when other GABAergics fail. Administered as a loading dose of 5 mg/kg 5\text{ mg/kg} 5 mg/kg IV over 10 minutes , followed by an infusion of 1 – 5 mg/kg/h 1\text{--}5\text{ mg/kg/h} 1 – 5 mg/kg/h . Pentobarbital carries profound systemic morbidity: severe myocardial depression requiring multiple vasopressors, peripheral vasodilation, paralytic ileus, immunosuppression with secondary pneumonia, and a prolonged half-life ( 15 – 50 hours 15\text{--}50\text{ hours} 15 – 50 hours ) due to saturable zero-order hepatic clearance.

Anesthetic Agent Loading Dose Maintenance Infusion Major Clinical Advantages Severe Critical Toxicities

Midazolam 0.2 mg/kg 0.2\text{ mg/kg} 0.2 mg/kg IV bolus 0.05 – 2.0 mg/kg/h 0.05\text{--}2.0\text{ mg/kg/h} 0.05 – 2.0 mg/kg/h Least hypotensive; rapid titration Tachyphylaxis; 1 -OH-midazolam 1\text{-OH-midazolam} 1 -OH-midazolam accumulation in renal dysfunction

Propofol 1 – 2 mg/kg 1\text{--}2\text{ mg/kg} 1 – 2 mg/kg IV bolus 2 – 10 mg/kg/h 2\text{--}10\text{ mg/kg/h} 2 – 10 mg/kg/h ; (approximately 33–167 micrograms/kg/min) Ultra-fast on/off kinetics; lowers intracranial pressure Propofol Infusion Syndrome (PRIS) ; severe hypotension/vasodilation

Pentobarbital 5 mg/kg 5\text{ mg/kg} 5 mg/kg IV over 10 min 10\text{ min} 10 min 1 – 5 mg/kg/h 1\text{--}5\text{ mg/kg/h} 1 – 5 mg/kg/h Direct chloride gating; highly effective for SRSE Profound myocardial depression; ileus; prolonged coma; infectious sepsis

Ketamine 1 – 2 mg/kg 1\text{--}2\text{ mg/kg} 1 – 2 mg/kg IV bolus 1 – 5 mg/kg/h 1\text{--}5\text{ mg/kg/h} 1 – 5 mg/kg/h Non-competitive NMDA blocker; supports hemodynamics Neuropsychiatric hallucinations; potential hypersalivation

Warning

Higher propofol doses and prolonged exposure increase PRIS risk, but a numerical dose or 48-hour cutoff does not guarantee safety below it. Use the minimum effective exposure, monitor clinically relevant metabolic, muscle, cardiac, and lipid findings, and stop propofol promptly if PRIS is suspected. Treat shock, arrhythmia, hyperkalemia, acidosis, and rhabdomyolysis; renal replacement or extracorporeal support is selected according to the organ failure, not automatically for every abnormal laboratory value.

EEG-Guided Anesthetic Treatment

Use continuous EEG to verify seizure control, because paralysis and sedation can conceal motor activity. Common endpoints include electrographic seizure cessation or selected burst suppression; a fixed interburst interval, suppression percentage, or number of bursts per printed page is not a universally established outcome-improving target. Not every residual periodic discharge is a seizure. Balance seizure burden against hypotension, infection, ileus, respiratory support, and prolonged drug accumulation.

Maintain control for an appropriate interval, commonly 24–48 hours before a cautious taper, while optimizing longer-acting antiseizure medication. The exact duration and taper depend on etiology, EEG evolution, prior recurrence, and toxicity. A recurrence requires prompt reassessment and treatment, not automatic repeated coma cycles without evaluating a treatable cause. Ensure loading doses and maintenance regimens are appropriate to kidney and liver function, protein binding, dialysis, and interactions.

Ketamine: The Mechanistic Antidote to Excitotoxicity

Given that prolonged status epilepticus is driven by NMDA receptor upregulation and GABA-A depletion, Ketamine —a non-competitive, open-channel N M D A NMDA NM D A receptor antagonist—represents the ideal mechanistic countermeasure. By binding the phencyclidine ( P C P PCP PCP ) site inside the NMDA ion channel pore, ketamine terminates calcium influx and halts excitotoxic cell death.

Clinical Implementation

Dosing: Loading dose of 1 – 2 mg/kg 1\text{--}2\text{ mg/kg} 1 – 2 mg/kg IV bolus , followed by continuous infusion titrated from 1.0 – 5.0 mg/kg/h 1.0\text{--}5.0\text{ mg/kg/h} 1.0 – 5.0 mg/kg/h (or higher in super-refractory cases).

Hemodynamic Synergy: Unlike propofol and barbiturates, ketamine stimulates sympathetic catecholamine release, maintaining systemic vascular resistance and cardiac contractility. Hemodynamic responses vary, and hypotension remains possible in catecholamine-depleted patients.

Early Introduction: Emerging neurocritical guidelines advocate introducing ketamine early in RSE (as a second-line or third-line anesthetic adjunct alongside midazolam or propofol) rather than relegating it as a terminal salvage therapy after pentobarbital failure.

Advanced Rescue Therapies for Super-Refractory Status Epilepticus

When continuous IV anesthetics and ketamine fail to control seizures beyond 24 hours, multi-modality rescue strategies are initiated:

Inhaled Volatile Anesthetics: Isoflurane or desflurane delivered via specialized ICU scavenging systems (AnaConDa). Volatile anesthetics provide profound GABAergic and two-pore domain potassium channel activation, achieving burst suppression within minutes. Prolonged use carries risks of isoflurane-induced posterior leukoencephalopathy, hypotension, and atelectasis.

Ketogenic Diet: Administered via enteral tube feeding using a 4:1 fat-to-(carbohydrate + protein) ratio . Metabolism shifts from glucose to ketone bodies ( β -hydroxybutyrate \beta\text{-hydroxybutyrate} β -hydroxybutyrate and acetoacetate), which promote GABA synthesis by upregulating glutamate decarboxylase, reduce reactive oxygen species, and directly inhibit vesicular glutamate transporter 2 ( V G L U T 2 VGLUT2 V G LU T 2 ).

Therapeutic Hypothermia ( 32 – 35 ∘ C 32\text{--}35^\circ\text{C} 32 – 3 5 ∘ C ): Lowers cerebral metabolic rate ( C M R O 2 CMRO_2 CMR O 2 ​ ), decreases glutamate release, and stabilizes the blood-brain barrier. (Note: the multicenter HYBERNATUS trial demonstrated no functional benefit in convulsive SE, but moderate hypothermia remains a rescue option in refractory SRSE).

Surgical Resection & Neuromodulation: Emergent lesionectomy or focal cortical resection if continuous EEG and structural MRI localize an acute focal epileptogenic structural substrate (e.g., cortical dysplasia, cavernoma, acute ischemic boundary zone). Vagus nerve stimulation ( V N S VNS V NS ) or electroconvulsive therapy ( E C T ECT ECT ) have documented rescue efficacy in isolated case series.

New-Onset Refractory Status Epilepticus (NORSE) & FIRES

New-Onset Refractory Status Epilepticus (NORSE) is an operational clinical syndrome—not a specific disease—defined as a rapid-onset refractory status epilepticus in a patient without active epilepsy or pre-existing relevant neurological disorder, and without an identifiable acute structural, toxic, or metabolic cause. When NORSE is preceded by a febrile illness occurring between 24 hours and 2 weeks prior to seizure onset, it is classified as Febrile Infection-Related Epilepsy Syndrome (FIRES) .

Etiology and Expert-Consensus Treatment

NORSE is a presentation, not proof of one disease or of an intrathecal cytokine storm in every patient. Investigate infectious, autoimmune, paraneoplastic, genetic, and other causes with appropriate MRI, CSF, serum studies, and malignancy evaluation. Preserve relevant specimens before immunotherapy when feasible without unsafe delay. Start empiric antimicrobial treatment when infection is plausible.

International consensus supports considering first-line immunotherapy within the first 72 hours, once common infectious causes are reasonably addressed, using specialist-directed corticosteroids and/or IVIG; plasma exchange is selected in context. Evidence is largely observational and consensus-based. Escalation, including ketogenic therapy and targeted immunotherapy, depends on suspected or identified etiology. Antibody-mediated disease and cryptogenic FIRES may call for different agents. Anakinra, tocilizumab, or rituximab are not a mandatory identical sequence with universally validated doses and timing. Consider infection, vaccination and screening requirements, cytopenias, organ function, and treatment interactions with the appropriate specialists.

A ketogenic diet requires a trained team, medication carbohydrate review, glucose and metabolic surveillance, and nutritional monitoring. Avoid concurrent high-dose propofol exposure when considering ketogenic therapy because of metabolic risk. Volatile anesthetics, neuromodulation, and epilepsy surgery are selected rescue approaches with limited evidence, not assured cures. Prolonged seizures warrant repeated etiologic review and family communication without assuming that duration alone proves irreversible injury.

Source: International NORSE/FIRES consensus .